The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Kate R. Woodworth, Danielle Moulia, Jennifer P. Collins, Stephen C. Hadler, Jefferson M. Jones, Sujan Reddy, Mary E. Chamberland, Doug Campos‐Outcalt, Rebecca L. Morgan, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Beth P. Bell, Matthew F. Daley, Sarah Mbaeyi, Kathleen Dooling, Sara E. Oliver
Abstract
The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years under an EUA is interim and will be updated as additional information becomes available. The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5-11 years, and ACIP determined benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.